Today: 15 May 2026
Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names
30 December 2025
2 mins read

Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

NEW YORK, December 30, 2025, 14:21 ET — Regular session

  • Karman Holdings shares fell in afternoon New York trade, lagging a subdued broader market.
  • Recent outflows from an aerospace and defense ETF have put the spotlight on fund-driven selling pressure.
  • Investors are watching whether the pullback stabilizes ahead of the company’s next quarterly update.

Karman Holdings Inc. shares were down 3.6% at $74.81 in afternoon trading on Tuesday, after touching $74.21 at the session low. The stock traded as high as $78.55, with about 465,000 shares changing hands.

The dip comes in the final week of the year, when thinner liquidity can exaggerate moves in individual stocks. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide, in a broader market note on holiday-thin trading.

Fund flows have also become a near-term focus for aerospace and defense names. Data cited by Nasdaq.com showed the SPDR S&P Aerospace & Defense ETF (XAR) saw an estimated $258.7 million outflow, or a 5.1% week-over-week drop in shares outstanding (from 20,475,000 to 19,425,000). A drop in shares outstanding typically reflects redemptions, meaning the fund can have to sell underlying holdings to meet investor withdrawals.

XAR is designed to track the aerospace and defense segment of the market, giving investors a one-ticket way to buy a basket of contractors and suppliers. State Street, which runs the ETF, says XAR aims to match the performance of the S&P Aerospace & Defense Select Industry Index before fees and expenses.

The sector tape looked steadier than Karman’s move suggested. XAR was down about 0.4% on Tuesday, while the SPDR S&P 500 ETF (SPY) was little changed, underscoring Karman’s sharper slide versus the broader market.

Karman, which does business as Karman Space & Defense, went public in February, when the company and selling shareholders raised $506 million in an upsized IPO that valued the defense and space systems maker at nearly $3 billion, Reuters reported.

In its most recent quarterly update in November, the company reported revenue of $121.8 million, up 41.7% from a year earlier. It also posted funded backlog of $758.2 million — a measure it defined as the invoiceable value of existing contracts, net of what has already been billed.

Karman said it raised and narrowed its full-year 2025 outlook, projecting revenue of $461 million to $463 million and non-GAAP adjusted EBITDA of $142 million to $143 million. Adjusted EBITDA is a profit yardstick that starts with earnings before interest, taxes, depreciation and amortization, then strips out selected items to show underlying operating performance.

The company also laid out a preliminary expectation for 2026 revenue growth of 20% to 25%, excluding future acquisitions. That makes the stock sensitive to shifts in sentiment around defense budgets, space launch spending and the cadence of government-backed programs that feed supplier order books.

In the near term, traders are watching whether Tuesday’s selloff holds near the bottom of the day’s range as year-end portfolio adjustments continue. In stocks with shorter public trading histories, flows — not headlines — can become the dominant driver for stretches of time.

Investors will also be watching for any fresh contract-related updates from primes and program owners that ripple down to suppliers, as well as any new filings that shed light on insider or institutional activity.

Stock Market Today

  • SPDR Portfolio High Yield Bond ETF (SPHY) Sees $151.5 Million Inflow
    May 15, 2026, 11:23 AM EDT. The SPDR Portfolio High Yield Bond ETF (SPHY) recorded a notable inflow of approximately $151.5 million, marking a 3.0% increase in outstanding units week over week, rising from 211.9 million to 218.3 million units. SPHY's share price last traded at $23.69, close to its 52-week high of $23.75 and well above its 52-week low of $21.80. The ETF's performance relative to its 200-day moving average, a key technical indicator used to assess trends, remains a point of interest for investors. Increased creation of units suggests growing demand, prompting purchases of underlying bond holdings and influencing the components within the ETF.

Latest articles

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

15 May 2026
Plug Power shares fell 1.7% to $3.725 in early Nasdaq trading Friday, following a volatile week after first-quarter results. The company reported a 22% revenue increase to $163.5 million and improved gross margin, but its net loss widened to $245.3 million and operating cash use rose to $150 million. Plug ended March with $802 million in cash and expects $142 million from a hydrogen asset sale in June.
Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

15 May 2026
Ford shares dropped 7% to $13.43 in early Friday trading, reversing part of a rally sparked by the launch of its new Ford Energy unit. The subsidiary, announced this week, will sell large battery energy storage systems to utilities and data centers, with first deliveries expected in late 2027. CEO Jim Farley said Ford is in the contracting phase with several customers. The stock had surged 13% Wednesday after Morgan Stanley highlighted the business.
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

15 May 2026
Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

15 May 2026
Nokia’s U.S.-listed shares dropped about 5% Friday, trading at $13.74 after a recent AI-driven surge. The decline followed a rally sparked by Cisco’s report of $5.3 billion in AI infrastructure orders from hyperscalers. Nokia saw a 54% jump in first-quarter operating profit and named Siemens’ Emma Falck as president of Mobile Infrastructure, effective September 1.
SSRM stock edges higher as gold rebounds — SSR Mining in focus ahead of Fed minutes
Previous Story

SSRM stock edges higher as gold rebounds — SSR Mining in focus ahead of Fed minutes

American Airlines stock edges up today as Chicago O’Hare expansion and storm fallout stay in focus
Next Story

American Airlines stock edges up today as Chicago O’Hare expansion and storm fallout stay in focus

Go toTop